According to the latest WHO's Global TB Report, there were an estimated 600,000 incident cases of MDR/RR-TB in 2016, with cases of MDR-TB which accounted for 82% (490,000) of the total. [1] Drug resistance surveillance data show that globally 4.1% of the new TB cases and 19% of the previously treated cases had MDR/RR-TB. [1] By the end of 2016, XDR-TB has been reported by 123 WHO Member States. Combining their data, the average proportion of MDR-TB cases with XDR-TB was 6.2%. [1] India accounts for one-fourth of the global TB burden. About 2.4% of all the new TB patients and 11.6% of previously treated TB cases in India have MDR-TB. [2] At the end of 2015, India had 79,000 cases of MDR/RR-TB [3] which is 11% >2014. Moreover, no data from patients treated in the public sector are available. It is estimated that 2.2 million cases of TB were treated in public sector in 2016 which could be anything between 1.9 million and 5.24 million by 2024. These projections were made based on the data from the sale of drugs containing rifampicin, the main anti-TB drug. [4] Untreated or inadequately treated patients of MDR/RR-TB are at increased risk of spreading their disease in the community, which could lead to outbreaks in vulnerable populations. Accurate and reliable laboratory drug-susceptibility testing (DST) data to second-line antituberculosis drugs (SLDs) are the basic requirement of the Directly Observed Treatment Short course-plus strategy, as they will support clinical decision-making and help to prevent the emergence of further drug resistance in patients with MDR-TB. [5] The aim of this study was to analyze the resistance to second-line anti-TB drugs of MDR and RR strains of M. tuberculosis isolated from presumptive DR-TB patients attending various chest clinics in Delhi.
Methods
The study was conducted at New Delhi Tuberculosis Centre (NDTC), Jawaharlal Nehru Marg, New Delhi. Started as a model clinic in 1940, NDTC is functioning as State Tuberculosis Training and Demonstration Center as well as Intermediate Reference Laboratory providing diagnostic and treatment follow-up services to 17 of the 25 Revised National Tuberculosis Control Program-designated TB districts (also called as chest clinics) in Delhi. The center is also responsible for the overall supervision of the external quality assurance activities of the entire state and is going through regular rounds of proficiency testing for smear microscopy as well as culture and DST by the National Reference Laboratory, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
A total of 372 culture-positive MDR and RR M. tuberculosis isolates were included in this study. All of them had been isolated from individual presumptive DR-TB patients (failures of new TB cases, contacts of known MDR-TB case, smear-positive previously treated pulmonary TB cases at diagnosis, and any follow-up smear positive in new or previously treated cases) attending various chest clinics in Delhi between January 1, 2017, and August 31, 2017. The identification of MDR/RR-TB was done by screening the sputum samples/culture isolates of these patients for the presence of most common mutations conferring resistance to isoniazid and rifampicin using the Genotype MTBDRplus assay version 2.0 (Hain Life Sciences, Nehran, Germany). All clinical strains had been identified initially as M. tuberculosis using the immunochromatographic Capilia test.
The drugs used for susceptibility testing of these MDR and RR MTB isolates were capreomycin (CAP), kanamycin (KAM), levofloxacin (LVX), moxifloxacin (MOX), clofazimine (CFZ), and linezolid (LZD). All test drugs were obtained in a chemically pure form M/s Sigma Aldrich. Except for CFZ and LZD, which are considered self-sterilizing, all stock solutions were filtered in a sterile manner with a 0.22 µm pore size polycarbonate filter. All stock solutions were stored at −80°C in small aliquots. Frozen drug solutions were thawed once before use and the leftover was then discarded.
The DST of MDR/RR MTB isolates was performed by 1% proportionate method using BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 system (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA) following the standard protocol. [6] Briefly, culture suspensions for inoculation were first well dispersed with no large visible clumps. After thorough mixing and homogenization of the culture suspensions, the tubes were allowed to rest for at least 15 min, and the supernatant was used to inoculate the drug-containing MGIT with OADC supplement. The tubes were then placed in the DST set carrier and entered into the MGIT 960 instrument as "unknown drugs" using the DST entry feature. [6] The final drug concentrations used were as follows: 2.5 µg/ml for CAP, 2.5 µg/ml for KAN, 1.5 µg/ml for LVX, 0.5 µg/ml and 2.0 µg/ml for MOX, 1.0 µg/ml for LZD, and 0.5 µg/ml for CFZ.
results
A total of 3000 GenoType MTBDRplus tests were conducted. Of these, 2898 were done directly on sputum samples and 102 indirectly using culture isolates. Of the 3000 tests conducted, 287 (9.5%) were found to have mutations conferring resistant to RIF and INH (MDR), whereas 95 (3.16%) had mutations conferring resistance to RIF only (RR). The detailed results are provided in Table 1 . Among the 382 MDR and RR samples identified, SLDs were performed in 372 (97.3%) samples. The remaining 10 (2.7%) samples were either culture negative or contaminated. These 374 MDR/RR MTB isolates were tested for susceptibility against KAN, CAP, LVX, MOX (0.5 µg/ml), MOX (2.0 µg/ml), CFZ, and LZD. Susceptibility patterns identified are presented in Table 2 . Two hundred and thirty-six (63.10%) strains were susceptible to all drugs, whereas 138 (36.89%) were resistant at least to one of the second-line drugs. Results showed that 18 (4.8%) of the 374 isolates tested were resistant to KAN, 24 (6.4%) to CAP, 127 (33.9%) to LVX, 4 (1.0%) to LZD, 86 (22.91%) to MOX (0.5 µg/ml), and 10 (2.6%) to MOX (2.0 µg/ml). Monoresistance to LVX, CAP, KAN, and MOX (0.5 µg/ml) was detected in 36 (9.6%), 3 (0.8%), 1 (0.2%), and 1 (0.2%) strains, respectively. Monoresistance to MOX (2.0 µg/ml), CFZ, and LZD was not detected. Resistance to two drugs in different combinations was found in 69 (18.5%) strains, resistance to three drugs was found in 25 (6.7%) strains, resistance to four drugs was found in 6 (1.6%) strains, and resistance to five drugs was found in only 1 (0.2%) strains. One hundred and sixteen (31.01%) strains were identified as, pre-XDR, most of the strains (108 [93.1%]) had additional fluoroquinolone resistance. Twenty-two (5.88%) of the isolates tested were identified as XDR.
dIscussIon
The present study attempted to systematically investigate the prevalence of second-line drug resistance among the pulmonary MDR and RR M. tuberculosis strains from presumptive DR-TB patients in Delhi who had not been previously exposed to second-line drugs in the form of antituberculous therapy. The increased knowledge of second-line drug resistance could be valuable for selection of an effective combination of second-line drugs for the treatment of MDR-TB. Resistance to KAN, CAP, LVX, MOX, CFZ, and LZD was analyzed in this study.
Among all the SLDs tested, at 33.9%, LVX resistance was highest, followed by 22.9% in MOX (0.5). Previous studies from various parts of India have reported high levels (3% to 35%) of fluoroquinolone resistance among MDR-TB patients. [7] [8] [9] [10] Eight-five (66.9%) of LVX-resistant strains were also resistant to MOX (0.5). This result is not surprising since cross-resistance between LVX and MOX has been reported in various studies. [11, 12] Two strains resistant to LVX were also resistant to CAP and one strain was resistant to LZD. According to the WHO's Global TB Report, among the 40 countries with a high TB or MDR-TB burden, the proportion of MDR-TB/RR-TB cases with resistance to any fluoroquinolone for which testing was done was 20%. [1] Thus, this study concurred with higher level of FQ resistance reported in the city and is slightly higher than the international data. This can be explained by the fact that fluoroquinolones are also the most widely prescribed class of antibiotics in the world today. Their broad spectrum of antibacterial activities and convenient dosing make them frequent choices for treating a variety of infections caused by susceptible organisms and for empiric therapy of common infections, such as pneumonia or sinusitis, where a causative organism has not been identified. A recent meta-analysis concluded that there is a threefold greater risk of FQ resistance among TB patients who are exposed to FQ before diagnosis of TB. [13] Resistance to KAN in this study was found to be 4.8%. CAP, the basic peptide antimicrobial agent with a mechanism of action similar to that of the aminoglycosides, is used in combination therapy for the treatment of MDR-TB. [14, 15] In the present study, the proportion of strains resistant to CAP (6.4%) was slightly higher than resistance to the KAN.
In most of the previous studies, across the world, a high rate of susceptibility to aminoglycosides among MDR-TB cases has been reported. [16, 17] However, some studies from Russia, Argentina, and India have reported higher rates of resistance to KAN, which might be partially explained by the administration of these drugs or analogs to previously treated patients as monotherapy. [18] The low levels of KAN resistance in the present study may be due to its limited use in the private sector perhaps because of its availability in injectable form.
CFZ and LZD are now recommended as core SLDs in the MDR-TB regimen according to recent classification. [19] Limited or no data from India are available on resistance of these two drugs. In the present study, CFZ was active against all (100%) the MDR and RR strains of M. tuberculosis, whereas 4 (1.0%) strains were resistant to LZD. Studies across the world support the results of this study. [20] Three of the LZD-resistant strains also had LVX resistance, whereas one had KAN and CAP resistance.
The proportion of XDR-TB isolates in this study was found to be 5.8% (22/372). The prevalence of XDR-TB among MDR-TB in India in various studies has been reported ranging from 0.89% to 33%. [4, 9, 10] conclusIon According to the present study, KAN was active against 95.2% of the strains, whereas CAP was active against 93.6% strains. The fluoroquinolones (LVX and MOX), on the other hand, were active against 66.1% and 74.3% strains, respectively. Alternative drugs are necessary for treating patients harboring resistance to LVX and MOX. The use of high-dose MOX for treating MDR/RR-TB patients is a suitable alternative as 97.4% strains were susceptible when tested at higher concentration (2.0 µg/ml) of MOX. The decision of adding CFZ and LZD to the core SLD group is supported by the results of this study as these two drugs were active against 100% and 99.0% of the strains, respectively. In addition, XDR-TB detected at the rate of 5.88% in the study despite being less the previous reports is still a matter of concern. India is a signatory to the WHO's "The End TB Strategy" with the aim to end the global TB epidemic and leave no-one behind; all efforts should be made to accelerate the rate at which TB incidence falls, together with an effective crisis response to contain the DR-TB epidemic, while it is still possible. This calls for early detection of such cases both from the public and private sector so that effective treatment can be started at the earliest and prevents the amplification and transmission of resistance in the community.
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